CEQUA Drug Patent Profile
✉ Email this page to a colleague
When do Cequa patents expire, and what generic alternatives are available?
Cequa is a drug marketed by Sun Pharm and is included in one NDA. There are four patents protecting this drug.
This drug has thirty-six patent family members in twenty-four countries.
The generic ingredient in CEQUA is cyclosporine. There are eighteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cequa
A generic version of CEQUA was approved as cyclosporine by HIKMA on October 29th, 1999.
Summary for CEQUA
| International Patents: | 36 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Patent Applications: | 4,337 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CEQUA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CEQUA |
| What excipients (inactive ingredients) are in CEQUA? | CEQUA excipients list |
| DailyMed Link: | CEQUA at DailyMed |
Pharmacology for CEQUA
| Drug Class | Calcineurin Inhibitor Immunosuppressant |
| Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
US Patents and Regulatory Information for CEQUA
CEQUA is protected by four US patents.
Patents protecting CEQUA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical cyclosporine-containing formulations and uses thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
Topical formulations and uses thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | CEQUA | cyclosporine | SOLUTION;OPHTHALMIC | 210913-001 | Aug 14, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | CEQUA | cyclosporine | SOLUTION;OPHTHALMIC | 210913-001 | Aug 14, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | CEQUA | cyclosporine | SOLUTION;OPHTHALMIC | 210913-001 | Aug 14, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | CEQUA | cyclosporine | SOLUTION;OPHTHALMIC | 210913-001 | Aug 14, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CEQUA
See the table below for patents covering CEQUA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2948387 | ⤷ Try a Trial | |
| Mexico | 2018010395 | FORMULACIONES TOPICAS QUE CONTIENEN CLICLOSPORINA Y USOS DE LAS MISMAS. (TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF.) | ⤷ Try a Trial |
| China | 109843316 | 含有环孢菌素的局部制剂及其用途 (TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF) | ⤷ Try a Trial |
| Australia | 2017227585 | Topical cyclosporine-containing formulations and uses thereof | ⤷ Try a Trial |
| European Patent Office | 3423076 | FORMULATIONS À USAGE TOPIQUE CONTENANT DE LA CYCLOSPORINE ET LEURS UTILISATIONS (TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CEQUA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2049079 | LUC00006 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
